Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Altered Function of Antigen-Presenting Cells in Type 1 Diabetes: A Challenge for Antigen-Specific Immunotherapy?

Diabetes - 1 Aug 2018

Creusot Rémi J, Postigo-Fernandez Jorge, Teteloshvili Nato

Abstract excerpt

Type 1 diabetes (T1D) arises from a failure to maintain tolerance to specific β-cell antigens. Antigen-specific immunotherapy (ASIT) aims to reestablish immune tolerance through the supply of pertinent antigens to specific cell types or environments that are suitable for eliciting tolerogenic responses. However, antigen-presenting cells (APCs) in T1D patients and in animal models of T1D are affected by a number...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigen Presentation
Share to Antigen-Presenting Cells
Share to Autoimmunity

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemotaxis

Share to Hypoglycemic Agents

Share to Immunotherapy

Share to Models, Immunological

Share to Phagocytosis

Source

Open in PubMed Open full text

Identifiers

PMID: 30030289
DOI: 10.2337/db17-1564
PMCID: PMC6054431

Genes

APC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Altered Function of Antigen-Presenting Cells in Type 1 Diabetes: A Challenge for Antigen-Specific Immunotherapy?PMID 30030289Read ↗

Progress and challenges for treating Type 1 diabetes.Semantic proximity Read ↗

Obstacles and opportunities for targeting the effector T cell response in type 1 diabetes.Semantic proximity Read ↗

The beta cell-immune cell interface in type 1 diabetes (T1D)Semantic proximity Read ↗

Activation of T cell checkpoint pathways during β-cell antigen presentation by engineered dendritic cells promotes protection of non-obese diabetic mice from type 1 diabetesSemantic proximity Read ↗

Type 1 diabetes genetic susceptibility and dendritic cell function: potential targets for treatment.Semantic proximity Read ↗

The Role of T Cell Receptor Signaling in the Development of Type 1 DiabetesSemantic proximity Read ↗

Factors Governing B Cell Recognition of Autoantigen and Function in Type 1 DiabetesSemantic proximity Read ↗

The Chicken or the Egg Dilemma: Understanding the Interplay between the Immune System and the β Cell in Type 1 Diabetes.Semantic proximity Read ↗

Memory T Cells in Type 1 Diabetes: the Devil is in the Detail.Semantic proximity Read ↗

Recent advances in understanding Type 1 DiabetesSemantic proximity Read ↗

Thymic B Cells as a New Player in the Type 1 Diabetes Response.Semantic proximity Read ↗

A comprehensive guide to antibody and T‐cell responses in type 1 diabetesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.